Come up with a name for your new list and we'll add to it:
Encore Vision raised a round of funding on September 17, 2014. Investors include
Steelhead Capital Management.
Encore Vision (EV) develops EV06, a clinical-stage, disease-modifying topical therapy for presbyopia. EV06 comprises a proprietary small molecule prodrug, which works with the eye's endogenous enzymes…